1. Scrip
  2. >>Business
  3. >>Deals

Novartis To Pay $9.7bn For The Medicines Company

Bid Follows Strong Data For Twice-Yearly Gene Silencing Cholesterol Lowerer

 
• By Eleanor Malone

Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.
Basel-based Novartis is acquiring The Medicines Company

Rumours that Novartis AG was in talks to acquire The Medicines Company were confirmed on 24 November with the announcement of a $9.7bn agreed deal. The acquisition brings it a soon-to-be-filed novel PCSK9 inhibitor that is poised to take on the incumbent drugs on the market with claims of greater convenience, excellent safety and comparable efficacy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.